Literature DB >> 25992204

Quality of life outcomes in patients with breast cancer.

Theofilou Paraskevi1.   

Abstract

Health-related quality of life is now considered an important endpoint in cancer clinical trials. It has been shown that assessing quality of life in cancer patients could contribute to improved treatment and could even serve as a prognostic factor along with medical parameters. This paper presents a review of quality of life outcomes in patients with breast cancer according to previous descriptive findings. This is a bibliographic review of the literature covering publications that appeared in English language biomedical journals between 1987 and 2008. The search strategy included a combination of the key words quality of life and breast cancer in the titles of published articles. The major findings are summarized and presented under different headings: evaluation of health-related quality of life i) at the time of diagnosis, ii) during treatment, and iii) after the completion of treatment. Breast cancer patients receiving chemotherapy might experience several side-effects and symptoms that have a negative effect on their quality of life. Also adjuvant hormonal therapies were found to have a similar negative impact on quality of life. Psychological distress-anxiety and depression were found to be common among breast cancer patients. Symptoms-pain, fatigue, and insomnia were among the most common symptoms reported. There was quite an extensive body of literature on quality of life in breast cancer patients. These papers have made a considerable contribution to improving breast cancer care.

Entities:  

Keywords:  breast cancer; mental health; quality of life; review; social function.

Year:  2012        PMID: 25992204      PMCID: PMC4419638          DOI: 10.4081/oncol.2012.e2

Source DB:  PubMed          Journal:  Oncol Rev        ISSN: 1970-5557


Introduction

Breast cancer is the most common cancer among women worldwide. Women are now diagnosed with the disease earlier and live longer. It is, therefore, crucial to consider the individual woman living with breast cancer and its treatment.[1] Quality of life has become a well-accepted outcome measure for cancer patients and an integral part of cancer patient management.[2-4] This is partly due to the increasing number of breast cancer patients. Statistics show that each year there is over 1.1 million newly diagnosed women with breast cancer worldwide and 410,000 women die from the disease.[5] On the other hand, improvements in early detection and treatment of breast cancer have led to longer survival of these patients. Also, breast cancer affects women's identities and, therefore, studying quality of life in women who lose their breasts is vital. In addition, women play an important role in family. When a woman develops breast cancer, all family members may develop some sort of illness.[6] The time of diagnosis, the initial stages of adjuvant treatment and the months immediately following completion of adjuvant treatment are transition times of poor adjustment and decreased quality of life in breast cancer patients.[7,8] Studies have shown that decreased health-related quality of life as a result of chemotherapy side-effects may predict early treatment discontinuation in these patients.[9] On the other hand, studies on post-treatment adjustment of breast cancer survivors demonstrated that breast cancer patients might benefit from a good quality of life.[10] However, according to other findings, the end of treatment can be exceedingly stressful for women with breast cancer, especially for those who have received adjuvant chemotherapy and/or radiation treatments.[11-15] Over the past ten years, much clinical effort has been directed to the treatment of breast cancer in order to improve survival. Now the question is: to what extent have studies of quality of life in breast cancer patients added to our understanding or contributed to improved outcomes in breast cancer care? This is very difficult to answer, but it is possible to try to investigate the contribution of quality of life studies to breast cancer care as a whole. There are several useful papers on quality of life in breast cancer patients. The aim of the present review is to collect and examine publications that have appeared between 1987 and 2008 in English language biomedical journals. It is hoped that this assessment may contribute to existing knowledge, provide both researchers and clinicians with a better profile on the topic, and consequently help improve quality of life in breast cancer patients.

Materials and Methods

As part of a study on quality of life in breast cancer patients, an extensive literature search was carried out using Medline, Embase, Scopus and PsychInfo database for articles published between 1987 and 2008. We chose 1987 as the earliest year for review to ensure that results would be consistent with current standards of care. To capture literature encompassing a broad set of domains that might be affected by breast cancer or its treatments, we included the following terms in our searches: breast cancer AND quality of life, fatigue, mental health, adjustment, social support, OR function. We use the term quality of life to be synonymous with the expression health-related quality of life. We confined our review to original reports of randomized trials and cohort studies. We excluded methodological articles, reviews, case series, and case reports, and non-English language articles.

Results and Discussion

Quality of life and breast cancer

Breast cancer is the most common malignancy among women worldwide. Approximately 230,480 new cases of invasive breast cancer and 39,520 deaths are expected among US women in 2011.[16] Approximately 78% of new cases and 87% of breast cancer deaths in 2011 will occur among women aged 50 years and older. In addition to invasive breast cancers, about 57,650 new diagnoses of in situ breast cancer are expected among US women in 2011.[16] Today, quality of life (QoL) surveys are an important issue in health care, especially in oncological research. Cancer affects different aspects of QoL and currently cancer is a major problem all over the world. The time of diagnosis, the initial stages of treatment and the months following completion of treatment are difficult times for patients both physically and emotionally. During these periods, poor adjustment and decreased QoL in breast cancer patients can easily occur.[17,18] Therefore, it is critical for health care professionals to become familiar with the impact of a breast cancer diagnosis and its treatment on patients' QoL.[19]

Quality of life among newly diagnosed patients

Initial diagnosis has been shown to evoke a state of shock, fear and disbelief, thus creating not only a psychological crisis but an existential one as well.[20] Most women experience at least some psychosocial distress during the course of their breast cancer diagnosis. The level of distress varies from woman to woman and can vary for the individual patient over the course of diagnosis. Cancer-related distress can be expected to dissipate with time for the majority of women diagnosed with cancer. For others, however, such distress may interfere substantially with comfort, QoL and the ability to make appropriate treatment decisions and adhere to treatment.[21,22] Most of the literature on the psychosocial aspects of breast cancer suggest that the vast majority of women adjust well to the diagnosis of breast cancer, and manage the complex and sometimes aggressive treatments associated with primary treatment and recurrent disease.[23-29] For a minority of women, however, a diagnosis of breast cancer contributes to significant psychosocial distress that can interfere with functioning and QoL.

Quality of life during the treatment

Primary treatment

Once the treatment plan is decided, women with breast cancer may experience some relief of anxiety and distress, but new fears may arise in anticipating and receiving the planned treatment. Surgery, particularly lumpectomy and axillary dissection, is often performed in an outpatient setting or under short stay procedure. Even the length of hospital stay for mastectomy has been shortened from that of just a few years ago. This means that someone must be available to assist the woman at home, particularly with household tasks or other activities that require arm mobility, and provide some nursing care (e.g. management of surgical drains and dressings). Women undergoing mastectomy and immediate reconstruction, especially with soft tissue flaps from the abdomen, will have a longer hospital stay and a more protracted recovery from surgery. A woman needs to be helped to understand what to expect with each of these procedures, and such preparation is important for her psychological well being and recovery.[30]

Adjuvant therapy

There is a wide range of adjuvant therapies, from tamoxifen as a single agent, to complex chemotherapy regimens with or without tamoxifen, to newer hormonal therapies. It is advisable for a woman to receive as much information and consultation as necessary before embarking on a course of adjuvant treatment. This helps to ensure that she understands which are the most appropriate for her, given her specific medical, personal, and social situation.[31-33] The process of gathering information is often stressful, but usually leads to a better understanding and acceptance of the treatment plan.[34,35] Most adjuvant chemotherapy is well tolerated, and women often continue many of their usual activities (childcare, household activities, paid employment), albeit often on a reduced schedule, especially modified by treatment administration. The difficulty here is that the receiver of adjuvant treatment is someone who is trying to recover physically and psychologically from a diagnosis of cancer and surgery, and adds additional associated physical symptoms for a period of from four to six months. While it is perceived by most women as a reasonable insurance policy' gainst subsequent breast cancer recurrence, adjuvant treatment significantly decreases quality of life during the treatment course.[34,35] After the initial shock of diagnosis and adjustment to treatment, much of the distress is connected to decisions that may impede quality of life and the need to adjust to such physical and emotional changes. Type of surgery, choice of chemotherapy when more than one choice is acceptable, type of radiation therapy (external beam, brachytherapy), and the decision to forgo hormonal suppression are some of the issues that have emotional consequences because they affect anxiety, mood, and stamina.[31-33]

Symptoms

Symptoms, such as hot flashes on tamoxifen treatment, have been reported to decrease general quality of life in women with breast cancer, either directly or through associated disturbed sleep and fatigue.[36] Fatigue from treatment, especially in association with pain or other symptoms, can increase anxiety and depression.[37] In a cross-sectional study of 841 patients, pain, fatigue, and insomnia were significantly related to loss of physical functioning, even after controlling for cancer treatment and comorbid conditions.[38] In a 1-year follow up of the same cohort, chemotherapy was related to reports of fatigue in the short term but not at 1-year post treatment.[39]

Mental health and overall impact

The processes of care, including feeling like one had a choice of treatment are also important predictors of health outcomes. For example, in one cohort of female patients, choice was independently associated with reports of better mental health.[40] Recently, Keating and colleagues extended these results and demonstrated that the concordance between desired and actual decision-making was more important than the actual process itself.[41] Receiving chemotherapy (yes vs. no) has not been related to any long-term mental health outcomes except for having a perception that breast cancer had a greater impact on one's life, even after considering stage and other factors.[40] One aspect of this negative impact has been distress about the weight gain associated with chemotherapy.[42]

Social and role function

Social and role functions are inextricably linked to social support and integration prior to breast cancer diagnosis. Breast cancer survivors who are more socially integrated before their diagnosis report better post-treatment role function and vitality than less socially integrated women.[43] In fact, Michael and colleagues report that social integration accounts for greater variance in quality of life than treatment itself.[43] As a result, others have developed social support interventions targeted to breast cancer survivors with poor support systems. In a recent randomized, prospective trial, the quality of life of older women improved when communicating with a community-based nurse case manager who provided help with managing comorbid conditions, assistance with activities of daily living (ADLs), and help in navigating the health care system.[44]

Caregiver burden

There is a paucity of data about the impact of breast cancer in older women on their family members and caregivers. Female gender, older age, and past grief experiences have been associated with increased distress and grief in spousal caregivers of cancer patients.[45] In one study, daughters and sisters of women with breast cancer perceived that their information and support needs were not well met.[46] In another report, Northouse and colleagues found that family members of patients with recurrent disease experienced decrements in emotional well being, and that negative impact was mediated by the ability of the family to deal with the situation and social support.[47] Overall, more research is needed to assess caregiver needs and develop appropriate interventions geared to older patients and their families.

Quality of life after the completion of treatment

At the end of primary breast cancer treatment, whether this is at the conclusion of six weeks of radiation therapy or after 4–6 months of adjuvant chemotherapy, most women experience a mixture of elation, fear, and uncertainty.[48] Although they have mastered the many aspects of their treatment regimen, they have little preparation and information to guide them in their recovery from treatment. The post-treatment transitional period is a time of considerable psychosocial distress. The paradoxical increase in anxiety has been observed at the end of both radiation and systemic chemotherapy.[49] Nevertheless, many women find positive meaning and describe posttraumatic growth from the cancer experience.[25] Nevertheless, fear of recurrence is frequently a dominant emotion that is difficult to control, especially before or during follow-up visits. There has been growing interest in the late effects of breast cancer treatment and the quality of life of long-term survivors beyond the acute phase of treatment. Several published studies have compared breast cancer survivors to healthy, age-matched populations of women and have found few differences in their long-term physical or emotional well being.[50,51] A recent study of long-term adjustment of women 20 years after treatment in a large multicenter clinical trial found cancer worries to be negligible; however, 18% of women had posttraumatic stress symptoms, and many reported lymphedema (27%) and numbness (20%) as persistent problems.[52] There is some evidence that women who receive adjuvant therapy may have more physical disruption than those who receive no further therapy, and that women who receive chemotherapy may have more sexual dysfunction, and possibly more cognitive dysfunction, than survivors who did not receive similar therapy.[53-57] With the growing number of breast cancer survivors, as well as increased research funding targeting this population, new evidence will emerge regarding these cognitive and psychosocial concerns.[58]

Conclusions

The need for psychosocial intervention amongst cancer patients cannot be understated. The goals of planning a psychosocial intervention in the Greek breast cancer context would be to support the patients' ability to cope with the stress of treatment, helping them to tolerate short-term loss for long-term gain, and to assist in symptom management.[59-61] However, owing to increased patient burden, in-depth psychological intervention to each patient may not be feasible, and some sort of mechanism to cater for to psychosocial problems needs to be identified. Recognizing the subset of women at risk is one such way forward, followed by targeted intervention, such as patient education and counselling.
  54 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning.

Authors:  P A Ganz; J H Rowland; K Desmond; B E Meyerowitz; G E Wyatt
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Bereavement of spouse caregivers of cancer patients.

Authors:  Ora Gilbar; Hasida Ben-Zur
Journal:  Am J Orthopsychiatry       Date:  2002-07

4.  Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer.

Authors:  J A McInnes; M T Knobf
Journal:  Oncol Nurs Forum       Date:  2001-05       Impact factor: 2.172

5.  Treatment decision making in early-stage breast cancer: should surgeons match patients' desired level of involvement?

Authors:  Nancy L Keating; Edward Guadagnoli; Mary Beth Landrum; Catherine Borbas; Jane C Weeks
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 6.  Quality of life and adjuvant systemic therapy for early-stage breast cancer.

Authors:  Peter S Grimison; Martin R Stockler
Journal:  Expert Rev Anticancer Ther       Date:  2007-08       Impact factor: 4.512

7.  Characteristics of women at risk for psychosocial distress in the year after breast cancer.

Authors:  C A Schag; P A Ganz; M L Polinsky; C Fred; K Hirji; L Petersen
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

8.  Someone to live for: social well-being, parenthood status, and decision-making in oncology.

Authors:  S B Yellen; D F Cella
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

Review 9.  Breast reconstruction--past achievements, current status and future goals.

Authors:  M Wickman
Journal:  Scand J Plast Reconstr Surg Hand Surg       Date:  1995-06

Review 10.  Women's psychological reactions to breast cancer.

Authors:  D K Payne; M D Sullivan; M J Massie
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

View more
  23 in total

1.  Preliminary Qualitative and Quantitative Evaluation of DESIREE, a Decision Support Platform for the Management of Primary Breast Cancer Patients.

Authors:  Sylvia Pelayo; Jacques Bouaud; Claudia Blancafort; Jean-Baptiste Lamy; Booma Devi Sekar; Nekane Larburu; Naiara Muro; Ander Urruticoechea Ribate; Jon Belloso; Guillermo Valderas; Sara Guardiola; Charlotte Ngo; Luis Teixeira; Gilles Guézennec; Brigitte Séroussi
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

2.  Cytokine Gene Polymorphisms Associated With Various Domains of Quality of Life in Women With Breast Cancer.

Authors:  Kimberly Alexander; Yvette P Conley; Jon D Levine; Bruce A Cooper; Steven M Paul; Judy Mastick; Claudia West; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2017-09-23       Impact factor: 3.612

3.  Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.

Authors:  Rana El Haidari; Amelie Anota; Tienhan S Dabakuyo-Yonli; Francis Guillemin; Thierry Conroy; Michel Velten; Damien Jolly; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Linda Abou Abbas; Virginie Nerich
Journal:  Qual Life Res       Date:  2022-05-19       Impact factor: 3.440

4.  Effects of a novel form of intraoperative radiation therapy on quality of life among patients with early-stage breast cancer.

Authors:  Courtney M Lattimore; Max O Meneveau; Gina R Petroni; Nikole E Varhegyi; Gabriella C Squeo; Timothy N Showalter; Shayna L Showalter
Journal:  Brachytherapy       Date:  2022-02-02       Impact factor: 2.441

5.  Effect of a technology-supported physical activity intervention on health-related quality of life, sleep, and processes of behavior change in cancer survivors: A randomized controlled trial.

Authors:  Somya Rastogi; Amye J Tevaarwerk; Mary Sesto; Brittany Van Remortel; Preshita Date; Ronald Gangnon; Keith Thraen-Borowski; Lisa Cadmus-Bertram
Journal:  Psychooncology       Date:  2020-10-04       Impact factor: 3.894

Review 6.  A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients.

Authors:  Paraskevi Theofilou; Helen Panagiotaki
Journal:  Oncol Rev       Date:  2012-06-13

Review 7.  Spontaneous regression of breast carcinoma: review of English publications from 1753 to 1897.

Authors:  Wilson I B Onuigbo
Journal:  Oncol Rev       Date:  2012-12-28

8.  Are Health Literacy and Patient Activation Related to Health Outcomes in Breast Cancer Patients?

Authors:  Chisom Kanu; Carolyn M Brown; Karen Rascati; Leticia R Moczygemba; Michael Mackert; Lalan Wilfong
Journal:  Health Lit Res Pract       Date:  2021-07-15

Review 9.  Breast cancer treatment and its effects on aging.

Authors:  Leslie Chang; Lauren S Weiner; Sheri J Hartman; Steve Horvath; Dilip Jeste; Paul S Mischel; Deborah M Kado
Journal:  J Geriatr Oncol       Date:  2018-08-02       Impact factor: 3.929

10.  The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q.

Authors:  Atilla Soran; Aykut Soyder; Serdar Ozbas; Vahit Ozmen; Hasan Karanlik; Abdullah Igci; Mahmut Muslumanoglu; Turkkan Evrensel; Zafer Canturk; Zafer Utkan; Cihangir Ozaslan; Cihan Uras; Umit Ugurlu; Cavit Col; Neslihan Cabioglu; Ali Uzunkoy; Bahadır M Gulluoglu; Ergun Erdem; Can Konca; Efe Sezgin
Journal:  Support Care Cancer       Date:  2020-11-26       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.